Idiopathic Pulmonary Fibrosis Treatment Market Expansion to be Persistent During 2018 – 2026
Idiopathic pulmonary
fibrosis (IPF) is a chronic lung disease distinguished by progressive
and irreversible reduction in lung function characterized by
thickening and damaging of the walls of the air sacs (called
alveoli). Common symptoms include, dry cough, gradual onset of
shortness of breath, nail clubbing, and fatigue. Other symptoms are
weight loss and muscle and joint pain. Further complications include,
hypertension, heart failure, pulmonary embolism or pneumonia.
Major factors
causing damage to the lungs include, acid reflux from stomach,
certain viruses such as Epstein Barr virus and herpes virus or
environmental factors such as breathing in dust such as silica dust,
asbestos fibers, hard metal dust, and coal dust. Treatments for
idiopathic pulmonary fibrosis (IPF) include, oxygen therapy,
pulmonary rehabilitation, symptom management, and lung transplant.
Prescribed antifibrotic drugs include, Pirfenidone and Nintedanib.
Request For A
Sample Copy Of This Research Report:
www.coherentmarketinsights.com/insight/request-sample/2466
Global Idiopathic
Pulmonary Fibrosis Treatment Market: Drivers
The idiopathic
pulmonary fibrosis treatment market size is expected to witness
significant growth, owing to increasing geriatric population.
According to National Institute of Health’s (NIH), 2015 report, the
symptoms of IPF starts occurring at the age of 50 to 70 in the U.S.
Moreover, increasing prevalence of idiopathic pulmonary fibrosis is
also expected to boost the market growth. According to NIH 2015
estimates, the prevalence of idiopathic pulmonary fibrosis is 13-20
per 100,000 people worldwide.
Smoking is believed
to be another cause of idiopathic pulmonary fibrosis. According to
the Centers for Disease Control and Prevention (CDC), around 1
billion smokers were recorded worldwide in 2017. The global
idiopathic pulmonary fibrosis treatment market revenue is expected to
witness significant growth, owing to availability of antifibrotic
drugs IPF such as Pirfenidone (Esbriet) and Nintedanib (Ofev).
According to annual reports of F. Hoffmann-La Roche AG, worldwide
sales of Esbriet in 2016 was US$ 753 million.
Global Idiopathic
Pulmonary Fibrosis Treatment Market: Restraints
Lack of awareness
and availability of proper treatment is expected to hinder the
idiopathic pulmonary fibrosis market growth. According to National
Center for Biotechnology Information (NCBI) 2017 report, 54% patients
do not receive any antifibrotic treatment in Europe.
Moreover,
misdiagnosis of IPF is also expected to hinder the idiopathic
pulmonary fibrosis treatment market size. For instance, according to
Multidisciplinary Respiratory Medicines (MRM), in 2012, around 50% of
IPF cases were misdiagnosed for other lung diseases in the U.S. High
cost associated with the treatment of idiopathic pulmonary fibrosis
is also expected to hinder the market growth. For instance, as per
the data published in American Journal of Managed Care (AJMC) in
2014, idiopathic pulmonary fibrosis treatment requires US$ 100,000
annually, in the U.S.
Global Idiopathic
Pulmonary Fibrosis Treatment Market: Competitive Landscape
Major players
operating in the global idiopathic pulmonary fibrosis treatment
market include, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb
Company, Cipla, F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV,
MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., and
Prometic Life Sciences Inc.
Global Idiopathic
Pulmonary Fibrosis Treatment Market: Regional Analysis
North America held
dominant position in the idiopathic pulmonary fibrosis market in
2017, owing to rising incidence of idiopathic pulmonary fibrosis.
According to NIH, 2015, around 100,000 people suffer from IPF and
30,000 to 40,000 new patients are diagnosed with the disease,
annually in the U.S. Moreover, increasing approval of new drugs is
also expected to boost the idiopathic pulmonary fibrosis treatment
market growth in the region. For instance, in 2015, Prometic Life
Sciences Inc. received the first orphan drug approval for PBI- 4050
from the U.S. Food and Drug Administration (FDA). Similarly, in 2017,
Plasminogen (Ryplazim) was approved as an orphan drug by the U.S.
FDA.
Click To
Read More On Idiopathic
Pulmonary Fibrosis Treatment Market
About
Coherent Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Comments
Post a Comment